Please use this identifier to cite or link to this item:
http://repositorio.fcmsantacasasp.edu.br/jspui/handle/FCMSCSP/51
Title: | Chronic microdose lithium treatment prevented memory loss and neurohistopathological changes in a transgenic mouse model of Alzheimer's disease |
Authors: | Caetano, Ariadiny de Lima Nunes, Marielza Andrade Schöwe, Natalia Mendes Silva, Karla Cristina Monteiro da Baraldi-Tornisielo, Ticiana Souza, Suzzanna Ingryd Gonçalves Balthazar, Janaina Albuquerque, Marilia Silva Viel, Tânia Araújo Buck, Hudson de Sousa |
Keywords: | Administration, oral Alzheimer disease Amnesia Animals Avoidance learning Brain-derived neurotrophic factor Cerebral cortex Cognition disorders Disease models, animal Drug administration schedule Gene expression Hippocampus Lithium carbonate Locomotion Male Maze learning Memory Mice Mice, transgenic Neuroprotective agents Plaque, amyloid |
Issue Date: | Nov-2015 |
Publisher: | PLoS One Public Library of Science |
Citation: | Nunes MA, Schöwe NM, Monteiro-Silva KC, Baraldi-Tornisielo T, Souza SI, Balthazar J, Albuquerque MS, Caetano AL, Viel TA, Buck HS. Chronic microdose lithium treatment prevented memory loss and neurohistopathological changes in a transgenic mouse model of Alzheimer's disease. PLoS One. 2015;10(11):e0142267. |
Abstract: | The use of lithium is well established in bipolar disorders and the benefits are being demonstrated in neurodegenerative disorders. Recently, our group showed that treatment with microdose lithium stabilized the cognitive deficits observed in Alzheimer's disease (AD) patients. In order to verify the lithium microdose potential in preventing the disease development, the aim of this work was to verify the effects of chronic treatment with microdose lithium given before and after the appearance of symptoms in a mouse model of a disease similar to AD. Transgenic mice (Cg-Tg(PDGFB-APPSwInd)20Lms/2J) and their non-transgenic litter mate genetic controls were treated with lithium carbonate (0.25mg/Kg/day in drinking water) for 16 or 8 months starting at two and ten months of age, respectively [corrected]. Similar groups were treated with water. At the end of treatments, both lithium treated transgenic groups and non-transgenic mice showed no memory disruption, different from what was observed in the water treated transgenic group. Transgenic mice treated with lithium since two months of age showed decreased number of senile plaques, no neuronal loss in cortex and hippocampus and increased BDNF density in cortex, when compared to non-treated transgenic mice. It is suitable to conclude that these data support the use of microdose lithium in the prevention and treatment of Alzheimer's disease, once the neurohistopathological characteristics of the disease were modified and the memory of transgenic animals was maintained. |
URI: | https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0142267 http://repositorio.fcmsantacasasp.edu.br/jspui/handle/FCMSCSP/51 |
ISSN: | 1932-6203 |
Appears in Collections: | Artigos |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
5. Chronic Microdose Lithium Treatment ....PDF | Acesso aberto | 5.42 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.